Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Portola: Solving the Huge Problem of the New Anticoagulants

May 18, 2016 0

Notwithstanding the unrelenting improvements being constantly made in managing blood coagulation’s problems, conventional anticoagulants still have …

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

May 17, 2016 0

COLLABORATIONS Preparing for the Future, Biogen Signs a Lucrative Collaborative Agreements While Highlighting the Small Firm …

Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms

May 16, 2016 0

Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief …

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

May 13, 2016 0

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of …

Giving to Gilead What Belongs to Gilead. Jazz Offers a Needed Relief

May 11, 2016 0

GILEAD After years of controversial refraining, official India reversed course and granted Gilead Sciences its patent …

Incyte Acquires Ariad Pharmaceuticals European Operations. See Also: A Great Achievement by Illumina

May 10, 2016 0

By June, which is next month, Incyte (INCY) will be the owner of the European operations …

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

May 9, 2016 0

EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved …

Prohost Letter #395

May 4, 2016 0

Prohost Letter #395 On the Road TO DEFEATING CANCER - Results of cancer treatment with novel immunotherapy …

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

May 2, 2016 0

GILEAD SCIENCES The people who cause the selloff of Gilead’s (GILD) stock because it missed 5 …

Who Will End Up Acquiring Medivation? Abbott Acquires St Jude. See Also: Alnylam

April 28, 2016 0

Medivation is a Target for Acquisition The Question is: Who Will Acquire Medivation? Sanofi has made a bid …

Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL

April 27, 2016 0

Biotech NEWS AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has …

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

April 26, 2016 0

Congratulations. The FDA approved Exelixis’ (EXEL) drug Cabometyx™ (cabozantinib) tablets for advanced renal cell carcinoma …

TapImmune and Loxo Oncology Have Interesting News

April 25, 2016 0

The AACR 2016 meeting presentations differed substantially from previous meetings. The 2016 meeting has brought near …

Why Illumina Might Be Offering a Lucrative Investment Opportunity

April 21, 2016 0

Illumina Showing 6% revenue increase over the same quarter last year, Q1 2016, was not enough as Illumina …

Nektar Therapeutics and Seattle Genetics at the AACR Meeting

April 19, 2016 0

Meaningful Presentations at the Annual Meeting of the American Association for Cancer Research (AACR) NEKTAR THERAPEUTICS …

Good News Does Not Always Mean Good Investment Opportunities

April 18, 2016 0

In the biotech sector, daily stories (news) are not just announced, but mostly edited in ways …

Gilead Files NDA for HBV Drug. Synta Surprising Merger

April 15, 2016 0

Pursuing its goal in treating hepatitis, Gilead Sciences (GILD) is at the finish line of clinical trials on …

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

April 13, 2016 0

Juno Therapeutics (JUNO) is due to receive a fee payment of $50 million from Celgene. The reason …

Regeneron in Gene Editing and New Information About CRISPR/Cas9 Gene Editing Firms

April 12, 2016 0

Regeneron and Intellia to Discover and Develop CRISPR/Cas Therapeutics Moving forward is Regeneron Pharmaceuticals’ (REGN) strategy based on strong …

Theravance Biopharma Drug Vibativ Overcomes Serious Infections. See Also: Juno Therapeutics in China

April 11, 2016 0

Dealing With Bacterial Resistance To Antibiotics In the NEWS THERAVANCE BIOPHARMA At the 26th European Congress …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Portola: Solving the Huge Problem of the New Anticoagulants

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

Giving to Gilead What Belongs to Gilead. Jazz Offers a Needed Relief

Incyte Acquires Ariad Pharmaceuticals European Operations. See Also: A Great Achievement by Illumina

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

Prohost Letter #395

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

Who Will End Up Acquiring Medivation? Abbott Acquires St Jude. See Also: Alnylam

Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

TapImmune and Loxo Oncology Have Interesting News

Why Illumina Might Be Offering a Lucrative Investment Opportunity

Nektar Therapeutics and Seattle Genetics at the AACR Meeting

Good News Does Not Always Mean Good Investment Opportunities

Gilead Files NDA for HBV Drug. Synta Surprising Merger

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

Regeneron in Gene Editing and New Information About CRISPR/Cas9 Gene Editing Firms

Theravance Biopharma Drug Vibativ Overcomes Serious Infections. See Also: Juno Therapeutics in China